ReviewLeukemia2008
Choosing between stem cell therapy and drugs in myelofibrosis.
Review in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 58 citations in OpenAlex.
- Repeat Endoscopy Affects Patient Management in Gastrointestinal Graft-Clinical hematology international · 2020Article
- Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation.European radiology · 2015Article
- Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study.European journal of nuclear medicine and molecular imaging · 2015Article
- (18)F-FDG PET/CT for Detection of Metachronous Hodgkin's Disease in Patients with Myelofibrosis.Nuclear medicine and molecular imaging · 2015Article
- Article
- How to manage the transplant question in myelofibrosis.Blood cancer journal · 2012Article
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.Nature reviews. Drug discovery · 2011Review
- Article
- The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.Bone marrow transplantation · 2010Article
- Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.Current hematologic malignancy reports · 2010Review
- Therapy of myelofibrosis (excluding JAK2 inhibitors).International journal of hematology · 2010Review
- Outcome of transplantation for myelofibrosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2010Article
- Article
- Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Journal of cellular and molecular medicine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal clinical management of patients with primary myelofibrosis and post-essential thrombocythemia/polycythemia vera myelofibrosis is a challenge, given the typically advanced age of presentation and variability of the disease course and prognosis. Current medical therapeutic options have not demonstrated an impact on the disease course, which exceeds the palliation of disease-related extramedullary hematopoiesis and alleviation of cytopenias. In contrast, allogeneic stem cell transplantation (SCT) can lead to 'cure' but is limited due to patient's age or comorbidities. Currently, in patients, who are reasonable candidates, SCT (frequently with a reduced intensity conditioning regimen) is employed for intermediate- to high-risk disease. Current pharmaco-medical therapy is used as a bridge to transplant, or instead of transplant in poor transplant candidates. Pathogenetic insights, especially the discovery of the Janus kinase (JAK)2(V617F) mutation, have ushered in a host of new potential therapeutic agents that may augment the role of medical therapy. Similarly, the boundaries of transplantation continue to alter with strategies that decrease conditioning-related toxicity, improved antimicrobial prophylaxis and decreased graft-versus-host disease. The potential for continued improvements in both medical and transplant therapy suggests that for the immediate future the optimal choices for an individual patient will remain potentially volatile and present complex decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.